Md. Code, Health - General § 18-110
This is the official text of Md. Code, Health - General § 18-110, part of Maryland’s Code, Health - General — covers public health regulation.
Not legal advice. This page reproduces the official text of a government statute for reference only. Laws change, and how a statute applies depends on your specific facts. For advice about your situation, consult a licensed attorney in your state.
§18–110.
Official statutory text
The Department, in partnership with the Department of Aging, the Virginia I. Jones Alzheimer’s Disease and Related Dementias Council, and the Greater Maryland Chapter of the Alzheimer’s Association, shall incorporate information into relevant public health outreach programs administered by the Department to:
(1) Educate health care providers regarding:
(i) The importance of early detection and timely diagnosis of cognitive impairment;
(ii) Validated assessment tools for the detection and diagnosis of cognitive impairment;
(iii) The value of a Medicare annual wellness visit or other annual physical for an individual at least 65 years old for cognitive health;
(iv) The Medicare care planning billing code for individuals with cognitive impairment; and
(v) Treatments approved by the Food and Drug Administration for Alzheimer’s disease and related dementias, including relevant information on treatment use and outcomes; and
(2) Increase public understanding and awareness of:
(i) The early warning signs of Alzheimer’s disease and related dementias;
(ii) The value of early detection, diagnosis, and treatment of Alzheimer’s disease and related dementias;
(iii) How to reduce the risk of cognitive decline, particularly among individuals in Black and Latino communities who are at greater risk of developing Alzheimer’s disease and related dementias; and
(iv) Treatments approved by the U.S. Food and Drug Administration for Alzheimer’s disease and related dementias and relevant information on treatment use and outcomes, including information related to treatment outcomes based on biological sex.
(1) Educate health care providers regarding:
(i) The importance of early detection and timely diagnosis of cognitive impairment;
(ii) Validated assessment tools for the detection and diagnosis of cognitive impairment;
(iii) The value of a Medicare annual wellness visit or other annual physical for an individual at least 65 years old for cognitive health;
(iv) The Medicare care planning billing code for individuals with cognitive impairment; and
(v) Treatments approved by the Food and Drug Administration for Alzheimer’s disease and related dementias, including relevant information on treatment use and outcomes; and
(2) Increase public understanding and awareness of:
(i) The early warning signs of Alzheimer’s disease and related dementias;
(ii) The value of early detection, diagnosis, and treatment of Alzheimer’s disease and related dementias;
(iii) How to reduce the risk of cognitive decline, particularly among individuals in Black and Latino communities who are at greater risk of developing Alzheimer’s disease and related dementias; and
(iv) Treatments approved by the U.S. Food and Drug Administration for Alzheimer’s disease and related dementias and relevant information on treatment use and outcomes, including information related to treatment outcomes based on biological sex.
Status: in_force · Read it on the official government site
Need a lawyer in Maryland?
Find a Maryland lawyer
About this page: Statute text is reproduced from official government publishers via the
Open US Law dataset
(Vaquill AI, snapshot v2026.08, CC BY 4.0). Primary legislative text like this is public domain under the government-edicts doctrine
(Georgia v. Public.Resource.Org, 2020). We link every section back to its official source so you can verify it independently.